28 results
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
oncology from 2018 and 2021, and vice president ethics and compliance from 2017 to 2018.
Anat Hakim
Ms. Hakim has held the role of executive vice … president, enterprise risk management and chief ethics and compliance officer of Lilly since 2021. Since joining Lilly in 1997, Mr. Weems has held
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
institutional review board, ethics committee or safety monitoring committee raising any material issues, including from any Regulatory Authority in any
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
institutional review board, ethics committee or safety monitoring committee raising any material issues, including from any Regulatory Authority in any
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
may begin and must be updated annually or when significant changes are made; approval by an Institutional Review Board (“IRB”) or independent ethics … to extensive negotiation and may vary significantly among different CROs and clinical trial sites; obtaining and maintaining IRB or ethics committee approval
DEF 14A
2dtqz
28 Apr 22
Definitive proxy
8:36am
424B3
9pmgs0ge1hf21s0tlcs
31 Mar 22
Prospectus supplement
11:42am
POS AM
jm1xt6e74
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
4yq 4wqw9jia90c7xr1
5 Aug 21
Prospectus supplement
4:26pm
424B3
ff78li9a
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
EX-10.13
uhd4pmkir oh
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4/A
22hbq445wgo2js1mph8f
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
EX-10.13
ex9tgjcap539tub
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm